BMKDF
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.00 | $6,910 | -$818,291 |
| 2025 Q2 | -0.00 | $6,871 | -$490,547 |
| 2025 Q1 | -0.00 | $38,992 | -$287,735 |
| 2025 Q4 | -0.00 | $38,992 | -$452,972 |
| 2024 Q3 | -0.00 | $38,563 | -$189,848 |
| 2024 Q2 | -0.01 | $38,348 | -$130,637 |
| 2024 Q1 | -0.01 | $38,313 | -$323,202 |
| 2024 Q4 | -0.00 | $39,805 | -$215,702 |